CD4 Expression Decrease by Antisense Oligonucleotides: Inhibition of Rat T CD4+Cell Reactivity
Open Access
- 1 August 2003
- journal article
- research article
- Published by Mary Ann Liebert Inc in Oligonucleotides
- Vol. 13 (4) , 217-228
- https://doi.org/10.1089/154545703322460603
Abstract
In previous studies, we have demonstrated the inhibition of CD4 expression in rat lymphocytes treated with phorbol myristate acetate (PMA) by antisense oligonucleotides (AS-ODNs) directed against the AUG start region of the cd4 gene. The aim of the present study was to inhibit CD4 expression in lymphocytes without promoting CD4 synthesis and to determine the effect of this inhibition on CD4+ T cell function. Four 21-mer ODNs against the rat cd4 gene (AS-CD4-1 to AS-CD4-4) were used. Surface CD4 expression was measured by immunofluorescence staining and flow cytometry, and mRNA CD4 expression was measured by RT-PCR. T CD4+ cell function was determined by specific and unspecific proliferative response of rat-primed lymphocytes. After 24 hours of incubation, AS-CD4-2 and AS-CD4-4 reduced lymphocyte surface CD4 expression by 40%. This effect remained for 72 hours and was not observed on other surface molecules, such as CD3, CD5, or CD8. CD4 mRNA expression was reduced up to 40% at 24 hours with AS-CD4-2 and AS-CD4-4. After 48 hours treatment, CD4 mRNA decreased up to 27% and 29% for AS-CD4-2 and AS-CD4-4, respectively. AS-CD4-2 and AS-CD4-4 inhibited T CD4+ cell proliferative response upon antigen-specific and unspecific stimuli. Therefore, AS-ODNs against CD4 molecules inhibited surface and mRNA CD4 expression, under physiologic turnover and, consequently, modulate T CD4+ cell reactivity.Keywords
This publication has 39 references indexed in Scilit:
- Gene therapy for arthritisGene Therapy, 2003
- Phase I Trial of ISIS 104838, a 2′-Methoxyethyl Modified Antisense Oligonucleotide Targeting Tumor Necrosis Factor-αThe Journal of Pharmacology and Experimental Therapeutics, 2002
- REDEFINING PERIPHERAL TOLERANCE IN THE BALB/C TO CBA MOUSE CARDIAC ALLOGRAFT MODELTransplantation, 1998
- Molecular Mechanisms of Antisense Drugs: RNase HAntisense and Nucleic Acid Drug Development, 1998
- Treatment with a Chimeric CD4 Monoclonal Antibody is Associated with a Relative Loss of CD4+/CD45RA+Cells in Patients with Rheumatoid ArthritisJournal of Autoimmunity, 1997
- Efficacy of Morpholino-modified Antisense Oligomers Directed against Tumor Necrosis Factor-α mRNAPublished by Elsevier ,1996
- Identification of a CD4 binding site on the β2 domain of HLA-DR moleculesNature, 1992
- Treatment of rats with monoclonal anti‐CD4 induces long‐term resistance to streptococcal cell wall‐induced arthritisEuropean Journal of Immunology, 1992
- The role of CD4 in T-cell activation: accessory molecule or co-receptor?Immunology Today, 1989
- Specific inhibition of lymphokine biosynthesis and autocrine growth using antisense oligonucleotides in Th1 and Th2 helper T cell clones.The Journal of Experimental Medicine, 1988